/stocks — the workspaceLOADING
Allogene Therapeutics, Inc. (ALLO) is a biological products, (no diagnostic substances) company. Piotroski F-Score 3/8. 9 insider Form 4 filings in the last 90 days. Next earnings projected around 2026-08-12 from ALLO's year-over-year reporting pattern (not yet company-confirmed). Fundamentals from SEC filings; prices are end-of-day.
EOD daily bars · delayed, not real-time · data: DatabentoCharting by TradingView Lightweight Charts™
XBRL company facts, SEC EDGAR. TTM = last four reported quarters. Valuation ratios arrive with a price source — we don't fake quotes.
FY ending 2025-12-31 vs 2024-12-31. original 1968 formula; calibrated on manufacturers, read financials/REITs with care
A plain-English read on ALLO plus an auto-SWOT — built from ALLO's SEC filings and market data, every point cited, nothing invented. Educational, not investment advice.
Four AI analysts — a bull, a bear, a risk manager, and a PM — debate ALLO using only the SEC-filing and market facts below. Every point cites its evidence; nothing is invented. This is educational research, not investment advice.
Educational only — not financial advice. Data from SEC EDGAR public filings; no live market data is shown. Figures reflect the company's own reported XBRL facts and may lag.
| Yoshiyama AnnieSVP, Finance | SELL | $22K | view → |
| Beneski Benjamin MachinasSVP, Chief Technical Officer | SELL | $7K | view → |
| Chang David DPresident and CEO | SELL | $118K | view → |
| Beneski Benjamin MachinasSVP, Chief Technical Officer | SELL | $12K | view → |
| Beneski Benjamin MachinasSVP, Chief Technical Officer | SELL | $19K | view → |
| Roberts ZacharyEVP of R&D | SELL | $63K | view → |
| Yoshiyama AnnieSVP, Finance | SELL | $7K | view → |
| Douglas Earl MartinSVP, General Counsel | SELL | $40K | view → |
Projected from ALLO's own SEC 8-K filing history — the year-over-year reporting pattern (~50% land the exact day, ~90% within a week). No analyst estimates, no scraped calendars, nothing invented. It upgrades to a confirmed date + time the moment ALLO files its announcement.
ALLO has sold off after 6 of its last 8 earnings reports.
Large earnings reactions have been common.
ALLO has traded lower after most recent earnings releases.
The average is inflated by its most volatile prints (+6.3% and -18.6%).
A more typical earnings reaction has been approximately ±6.6%.
Realized close-to-close history only — no options-implied move, no analyst estimates.
| Reported | Close-to-close |
|---|---|
| 2026-05-13 | -7.0% |
| 2026-03-12 | -8.7% |
| 2025-11-06 | +6.3% |
| 2025-08-13 | +3.9% |
| 2025-05-13 | -18.6% |
| 2025-03-13 | -5.8% |
| 2024-11-07 |
Earnings dates are the company's 8-K Item 2.02 filings (SEC). Reactions from Databento EOD.
| -4.3% |
| 2024-08-07 | -7.5% |